174 related articles for article (PubMed ID: 3111667)
61. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
62. Does alternate-day cloprednol therapy prevent bone loss? A longitudinal double-blind, controlled clinical study.
Medici TC; Rüegsegger P
Clin Pharmacol Ther; 1990 Oct; 48(4):455-66. PubMed ID: 2225706
[TBL] [Abstract][Full Text] [Related]
63. Growth and glucocorticoids in children with kidney disease.
Travis LB; Chesney R; McEnery P; Moel D; Pennisi A; Potter D; Talwalkar YB; Wolff E
Kidney Int; 1978 Oct; 14(4):365-8. PubMed ID: 366232
[TBL] [Abstract][Full Text] [Related]
64. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
Rice ML; Wong B; Horn PS; Yang MB
J AAPOS; 2018 Jun; 22(3):192-196. PubMed ID: 29733899
[TBL] [Abstract][Full Text] [Related]
65. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
66. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
Broyer M; Terzi F; Lehnert A; Gagnadoux MF; Guest G; Niaudet P
Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
[TBL] [Abstract][Full Text] [Related]
67. Differential effect of glucocorticoids on calcium absorption and bone mass.
Gennari C
Br J Rheumatol; 1993 May; 32 Suppl 2():11-4. PubMed ID: 8495275
[TBL] [Abstract][Full Text] [Related]
68. Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.
Eberhardt R; Krüger K; Reiter W; Gross W; Zwingers T
Arzneimittelforschung; 1994 May; 44(5):642-7. PubMed ID: 8024639
[TBL] [Abstract][Full Text] [Related]
69. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
Reitter B
Brain Dev; 1995; 17 Suppl():39-43. PubMed ID: 8882570
[TBL] [Abstract][Full Text] [Related]
70. Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients.
Ferraris JR; Pasqualini T; Alonso G; Legal S; Sorroche P; Galich AM; Jasper H;
Pediatr Nephrol; 2007 May; 22(5):734-41. PubMed ID: 17294225
[TBL] [Abstract][Full Text] [Related]
71. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2001; (2):CD001533. PubMed ID: 11405997
[TBL] [Abstract][Full Text] [Related]
72. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2000; (4):CD001533. PubMed ID: 11034723
[TBL] [Abstract][Full Text] [Related]
73. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation.
Briner VA; Thiel G; Monier-Faugere MC; Bognar B; Landmann J; Kamber V; Malluche HH
Transplantation; 1995 May; 59(10):1393-400. PubMed ID: 7770924
[TBL] [Abstract][Full Text] [Related]
74. Immunosuppressive activity of deflazacort in pediatric renal transplantation.
Ferraris JR; Tambutti ML; Redal M; Ramirez JA; Carlin MC; Samaniego MC; Prigoshin N
Transplantation; 1996 Aug; 62(3):417-20. PubMed ID: 8779694
[No Abstract] [Full Text] [Related]
75. Sequential changes of biochemical bone parameters after kidney transplantation.
Reinhardt W; Bartelworth H; Jockenhövel F; Schmidt-Gayk H; Witzke O; Wagner K; Heemann UW; Reinwein D; Philipp T; Mann K
Nephrol Dial Transplant; 1998 Feb; 13(2):436-42. PubMed ID: 9509459
[TBL] [Abstract][Full Text] [Related]
76. Does deflazacort therapy offer any advantages over conventional corticosteroids in children with renal disease?
Clark G
Pediatr Nephrol; 1997 Jun; 11(3):394. PubMed ID: 9203206
[No Abstract] [Full Text] [Related]
77. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
Portale AA; Booth BE; Halloran BP; Morris RC
J Clin Invest; 1984 Jun; 73(6):1580-9. PubMed ID: 6547151
[TBL] [Abstract][Full Text] [Related]
78. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
Campbell C; Jacob P
BMC Neurol; 2003 Sep; 3():7. PubMed ID: 12962544
[TBL] [Abstract][Full Text] [Related]
79. Long-term therapy with deflazacort in chronic sarcoidosis.
Rizzato G; Fraioli P; Montemurro L
Chest; 1991 Feb; 99(2):301-9. PubMed ID: 1846572
[TBL] [Abstract][Full Text] [Related]
80. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids.
Simon D; Fernando C; Czernichow P; Prieur AM
J Rheumatol; 2002 Jun; 29(6):1296-300. PubMed ID: 12064849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
